This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Constitution of Cerebrospinal Fluid and Blood Database/Specimen in Acute Stage of Subarachnoid Hemorrhage (aSAH) Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by Karl-Michael Schebesch, University of Regensburg.
Recruitment status was:  Recruiting
Technische Universität München
Information provided by (Responsible Party):
Karl-Michael Schebesch, University of Regensburg Identifier:
First received: February 8, 2011
Last updated: December 4, 2014
Last verified: December 2014
Neuropeptide Y (NPY) may play a major role in the pathophysiology of aneurysmal subarachnoid hemorrhage (aSAH). To investigate the correlation of NPY in cerebrospinal fluid (CSF) and blood (serum) and the neurological outcome in the acute stage of aSAH.

Subarachnoid Hemorrhage

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Possible Role of Neuropeptide Y After Spontaneous Subarachnoid Hemorrhage

Resource links provided by NLM:

Further study details as provided by Karl-Michael Schebesch, University of Regensburg:

Primary Outcome Measures:
  • Glasgow Outcome Scale [ Time Frame: 2011-2016 ]

Biospecimen Retention:   Samples Without DNA
cerebrospinal fluid / serum

Estimated Enrollment: 90
Study Start Date: January 2006
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage
control group
no neurological disease but spinal anesthesia

Detailed Description:
Evaluation of Neuropeptides in CSF and serum in SAH patients

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
consecutive pts. with subarachnoid hemorrhage

Inclusion Criteria:

  • spontaneous or aneurysmal subarachnoid hemorrhage

Exclusion Criteria:

  • age younger than 18 years or older than 70 years
  • inflammatory disease
  • history of former SAH
  • no ventricular drainage
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01292278

Department of Neurosurgery Medical Center University of Regensburg Recruiting
Regensburg, Germany, 93053
Contact: Karl-Michael Schebesch, M.D.    ++49 +941 944 9010   
Principal Investigator: Karl-Michael Schebesch, M.D.         
Sponsors and Collaborators
University of Regensburg
Technische Universität München
  More Information

Responsible Party: Karl-Michael Schebesch, Karl-Michael Schebesch, MD, University of Regensburg Identifier: NCT01292278     History of Changes
Other Study ID Numbers: CSF 06/179
Study First Received: February 8, 2011
Last Updated: December 4, 2014

Keywords provided by Karl-Michael Schebesch, University of Regensburg:
subarachnoid hemorrhage
cerebral vasospasm
neuropeptide Y

Additional relevant MeSH terms:
Subarachnoid Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on August 21, 2017